Novel inhibitor of brain indoleamine 2,3 dioxygenase, docking and experimental studies

Authors

  • Shazia Dawood Department of Biochemistry United Medical and Dental College Karachi
  • Samina Bano Clinical Biochemistry and Psychopharmacology Research Unit Department of Biochemistry University of Karachi

DOI:

https://doi.org/10.3329/icpj.v6i6.34180

Keywords:

Indoleamine 2, 3-dioxygenase, tryptophan, Molegro Virtual Docker, Hypericum perforatum, cytokines, N-formyl kynurenine

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a haem-containing monomeric enzyme that catalyze the conversion of tryptophan (L-TRP) to N-formyl kynurenine. IDO activity is regulated by cytokines. Pro inflammatory cytokines are potent inducers of IDO, whereas anti-inflammatory cytokines are IDO inhibitors. Prostaglandin E2 induces IDO activity. In inflammation the relationship between immune system and the kynurenine pathway play an important role. IDO is an important therapeutic target for the treatment of inflammation. Present study evaluates the binding of Hypericum perforatum (HP) against IDO enzyme using MVD software acute and chronic effects of HP on IDO enzyme activity. Docking results show that HP fit well in the allosteric site of IDO. Energy scores for HP -158.687 Kcal/mol. Administration of HP (500mg/kg/3ml) shows that serum IDO activity was significantly increased (171%, P<0.01) and (114%, P<0.01) respectively after acute and chronic treatment. Brain IDO activity was decreased by 42%, (P<0.01) after acute and 43% (P<0.01) chronic treatment. It is concluded from the present study that HP is noncompetitive inhibitor of IDO as proofs by docking further its inhibitory effects on brain IDO reveals its anti-inflammatory effect.

Dawood and Bano, International Current Pharmaceutical Journal, May 2017, 6(6): 34-39

http://www.icpjonline.com/documents/Vol6Issue6/01.pdf

Downloads

Download data is not yet available.
Abstract
2
PDF
2

Downloads

Published

2017-10-03

How to Cite

Dawood, S., & Bano, S. (2017). Novel inhibitor of brain indoleamine 2,3 dioxygenase, docking and experimental studies. International Current Pharmaceutical Journal, 6(6), 34–39. https://doi.org/10.3329/icpj.v6i6.34180

Issue

Vol. 6 No. 6 (2017)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).